2-(trifluoromethanesulfonyloxy)-propanoic acid benzyl ester | 494751-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(trifluoromethanesulfonyloxy)-propanoic acid benzyl ester
• 英文别名: benzyl 2-trifluoromethanesulfonyloxypropionate；D-1-benzyloxycarbonylethyl triflate；benzyl 2-trifluoromethanesulfonyl-oxypropionate；benzyl 2-(trifluoromethylsulfonyloxy)propanoate
• CAS: 494751-24-5
• 化学式: C₁₁H₁₁F₃O₅S
• 分子量: 312.267
• InChiKey: OCZJJSVVVXDQQC-UHFFFAOYSA-N

物化性质

• 沸点：
  333.8±42.0 °C(Predicted)
• 密度：
  1.423±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(trifluoromethanesulfonyloxy)-propanoic acid benzyl ester 在 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  N-[（1S，2S）-3-（4-氯苯基）-2-（3-氰基苯基）-1-甲基丙基] -2-甲基-2-{[[5-（三氟甲基）吡啶-2-基] oxy}丙酰胺（MK-0364），一种新型的无环大麻素-1受体反向激动剂，用于治疗肥胖症。

  摘要：

  描述了新型无环酰胺大麻素-1受体反向激动剂的发现。它们有效，选择性，口服可生物利用，并且在啮齿类动物的食物摄入和体重减轻模型中具有活性。优化过程的主要重点是提高体内功效并减少形成反应性代谢产物的可能性。这些努力导致鉴定出化合物48以开发为治疗肥胖症的临床候选者。

  DOI：

  10.1021/jm060996+
• 作为产物：
  描述：

  三氟甲磺酸酐 、 乳酸苄酯 在 2,6-二甲基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 2-(trifluoromethanesulfonyloxy)-propanoic acid benzyl ester
  参考文献：
  名称：

  轻度碱促进未活化的sp3-碳亲电试剂与烯基硼酸的亲核取代

  摘要：

  在温和的碱（例如K 3 PO 4）存在下，不同的烯基硼酸与各种sp 3-碳亲电试剂（例如未活化的烷基三氟甲磺酸酯）平滑反应。反应方案非常温和，因此可以实现较高的官能团耐受性。这种无过渡金属的条件与经典的过渡金属催化的Suzuki偶联正交。

  DOI：

  10.1002/adsc.201800826

文献信息

• Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy
  申请人：Schering AG

  公开号：US20030206865A1

  公开（公告）日：2003-11-06

  The invention relates to conjugates that consist of macrocyclic metal complexes with biomolecules and their production. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as as agents for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of the relaxivity is made possible.

  该发明涉及由大环金属配合物与生物分子组成的共轭物及其制备。这些共轭物适用于核磁共振诊断和放射诊断中作为对比介质，同时也适用于放射治疗剂。通过对大环化合物进行特殊配位，实现了高松弛度，并且可以实现对松弛度的精细调节。
• Macrocyclic metal complexes and their use for the production of conjugates with biomolecules
  申请人：Schering AG

  公开号：US20030108486A1

  公开（公告）日：2003-06-12

  The invention relates to macrocyclic metal complexes and their production and use for the production of conjugates with biomolecules. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of the relaxivity is made possible.

  该发明涉及大环金属配合物及其生产和用于与生物分子结合物的生产。这些结合物适用于核磁共振诊断和放射诊断中作为对比介质，也适用于放射治疗。通过对大环化合物进行特殊配位，实现了高弛豫率，并且可以进行弛豫率的精细调节。
• [EN] SUBSTITUTED AMIDES<br/>[FR] AMIDES SUBSTITUES
  申请人：MERCK & CO INC

  公开号：WO2003077847A2

  公开（公告）日：2003-09-25

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和格林-巴利综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• Substituted amides
  申请人：Lin S. Linus

  公开号：US20060106071A1

  公开（公告）日：2006-05-18

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（包括多发性硬化症和格林-巴利综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠梗阻和肝硬化的治疗。
• Substituted pyridyoxy amides
  申请人：Merck & Co., Inc.

  公开号：US07550489B2

  公开（公告）日：2009-06-23

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是Cannabinoid-1（CB1）受体的拮抗剂和/或逆向激动剂，并且在治疗、预防和抑制由CB1受体介导的疾病方面是有用的。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合症）以及病毒性脑炎、脑血管意外和头部创伤的炎性后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。